Cord Blood and Tissue Research and Trials
Overview:
This study is being conducted by researchers at the China Medical University Hospital in Taiwan. The purpose of the study is to determine the safety and effectiveness of brain transplants of CD34+ stem cells obtained from umbilical cord blood. The aim is to recruit participants between 35 years to 70 years of age who have had an ischaemic stroke more than 6 months and less than 60 months ago. Participants will receive umbilical cord blood stem cells injected into the brain around the site damaged by stroke, in combination with antiplatelet medication and rehabilitation. The donor (allogeneic) cord blood units will be obtained from cord blood banks in USA and Taiwan and will be closely HLA ‘matched’ to the recipient.
Location: Taichung, Taiwan
Trial design: Safety and efficacy
Status: Not yet recruiting
Find out more
Umbilical cord tissue is stored now with the intention that it may be used in the future for regenerative medicine therapies. Cord tissue is a rich source of mesenchymal stem cells that can regenerate cartilage, bone and other cell types.
Although research using MSC’s is still at an early stage, the unique properties of these cells make them promising for future cellular therapies. There are numerous clinical studies looking at the role of MSC’s in a wide variety of conditions.
Overview:
This study is being conducted by researchers at the General Hospital of Chinese Armed Police Forces. 40 patients with traumatic spinal cord injury (20 cases in the acute stage of injury and 20 in the later sequela stage) will receive mesenchymal stem cells (MSC’s) derived from umbilical cord tissue. The study is targeting adult patients with spinal cord injury between the ages of 20 and 50 years.
The MSC’s from human umbilical cord are transplanted directly by injection (lumbar puncture) into the subarachnoid space in the spine. Investigators also plan to follow up 10 patients who receive only rehabilitation and another 10 patients as a control group who accept neither stem cell therapy nor rehabilitation. On this basis, the researchers can compare the efficacy of these two treatments.
Location: Beijing, China
Trial design: Safety and efficacy
Status: Open
Find out more
Overview:
This trial aims to evaluate the use of stem cells from umbilical cord in the treatment of heart failure. The trial is being conducted at the Universidad de los Andes in Santiago. 30 participants will have their cardiac function carefully calibrated and recorded three months prior to the commencement of the trial, and be randomly assigned into one of two groups. The experimental group will receive a single intravenous (IV) injection of mesenchymal stem cells that have been obtained from donated cord blood. The control group will receive a placebo intravenous injection. Participants will be monitored for complications and changes in clinical conditions at three monthly intervals for one year.
Location: Santiago, Chile
Trial design: Safety and efficacy
Status: Recruiting
Find out more